Spotlight On... GE on the move: HQ moving to Boston, Healthcare to Chicago; Lantheus sells Canadian radiopharmacuticals biz; Pulmonx completes trial enrollment; and more...

General Electric ($GE) is moving its corporate headquarters from Fairfield, CT, to Boston. The move was likely inspired by the growing desire of workers to live in urban areas. Regardless, Boston's booming med tech (and biopharma) scene will be a boon for the company's device unit. In fact the company said it will move 600 digital industry product managers to the new HQ, including some in charge of life science-related technology. But GE Healthcare will now be based in Chicago, instead of the U.K., as previously reported. GE also announced that it is adding 100 jobs to its Global Research Center in Niskayuna, NY, which may be a consolation prize, for the state also made a bid to secure the new headquarters. More on the new HQ | Here's more about the R&D facility

@FierceMedDev: Medical device sales reps scouting out new jobs in 2016: Report. More | Follow @FierceMedDev

@EmilyWFierce: Olympus, FDA implicated in Senate probe of duodenoscope devices. Report | Follow @EmilyWFierce

> Lantheus has divested its Canadian radiopharmaceuticals to Isologic Innovative Radiopharmaceuticals for $9 million. More

> Pulmonx has completed enrollment of the IMPACT study in homogeneous emphysema patients for its Zephyr Endobronchial Valve, which is already in the U.S. pivotal LIBERATE trial. More

> GE Healthcare ($GE) and the Federal Economic Development Agency for Southern Ontario (FedDev Ontario) have committed $40 million to build a center for advanced therapeutic cell technologies in Toronto. More

Biotech News

@FierceBiotech: Biden maps out a 'moonshot' approach to cancer with plans to 'break down silos' in R&D. More | Follow @FierceBiotech

@JohnCFierce: FDA slaps down BioMarin's Duchenne's drug as rival nears a moment of truth. News | Follow @JohnCFierce

@DamianFierce: "I made a point to talk to female guests," he said. More from Bloomberg | Follow @DamianFierce

> Celgene chief Bob Hugin ponders a new era for neurodegeneration R&D. Report

> Pfizer looks to cut the line in CAR-T with off-the-shelf approach. Article

> Biotech has a problem with women? Or is it the other way around? More

Pharma News

@FiercePharma: U.S.-based Certara creates drug developing consultancy in China. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: J&J will boost workforce at South Africa consumer meds plant after $18M upgrade. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce:   head Slaoui says the company's vax and  businesses need each other--aka, no break-up, please. Article | Follow @CarlyHFierce

> For its next pare-down move, Pfizer weighs sale of Hospira pump business: Bloomberg. More

> FTC stats show pharma backing off pay-for-delay deals after SCOTUS ruling. Report

> Pfizer expands consumer biz in China with Treerly supplements buy. Article

Pharma Manufacturing News

> U.K.'s Oxford BioMedica gets MHRA nod for new manufacturing facility. Item

> GSK turns to K+N for supplier logistics. News

> FDA finds issues with Walgreens' infusion compounding services. Report

> EMA says Spain has taken action against drugmaker for shortcomings. Story

> Bayer opens large China plant for traditional Chinese and Western OTC meds. Article

CRO News

> Evotec hits an R&D milestone with J&J in an ambitious Alzheimer's collaboration. News

> Eurofins buys Dutch drug-testing firm to pad its services. More

> AMRI signs a trio of deals in R&D, manufacturing and marketing. Report

> Catalent inks a $619M deal to help Roche develop targeted therapies. Article

Pharma Asia News

> China-focused CASI Pharmaceuticals gets Marqbio review by CFDA. Item

> China continues to find problems in drug production. Article

> In Japan, fast approvals, more R&D cash and price cuts ahead. Report

> Astellas, Medivation report successful enzalutamide mCRPC PhII data in Lancet. More

> Cipla says top 50 drugs in development could bring in $30B. Story

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.